IDIX/ZGEN, non-gen1 HCV
ok point well taken - gen-4 does not comprise a significant commercial opportunity. for those with gen-4, given it too has a low svr with current soc, it could represent a breakthrough, and from a scientific standpoint it is at least notable that the idix compound has broader coverage. both might be used in gen-2, but time will tell. and yes a nuke is unique in having high potency against gen-2 and 3 which are still fairly prevalent in developed nations. which leads me to of course my favorite topic - interferon will still be needed for these genotypes for the foreseeable future since nukes woudl likely never have requisite efficacy as monotherapy
Market Data 
Markets 
AI
